IQGAP1 controls tight junction formation through differential regulation of claudin recruitment

IQGAP1 is a scaffolding protein previously implicated in adherens junction formation. However, its role in the establishment or maintenance of tight junctions (TJs) has not been explored. We hypothesized that IQGAP1 could regulate TJ formation by modulating the expression and/or localization of junc...

Full description

Saved in:
Bibliographic Details
Published inJournal of cell science Vol. 128; no. 5; pp. 853 - 862
Main Authors Tanos, Barbara E, Perez Bay, Andres E, Salvarezza, Susana, Vivanco, Igor, Mellinghoff, Ingo, Osman, Mahasin, Sacks, David B, Rodriguez-Boulan, Enrique
Format Journal Article
LanguageEnglish
Published England The Company of Biologists 01.03.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:IQGAP1 is a scaffolding protein previously implicated in adherens junction formation. However, its role in the establishment or maintenance of tight junctions (TJs) has not been explored. We hypothesized that IQGAP1 could regulate TJ formation by modulating the expression and/or localization of junctional proteins, and we systematically tested this hypothesis in the model Madin-Darby canine kidney (MDCK) cell line. We find that IQGAP1 silencing enhances a transient increase in transepithelial electrical resistance (TER) observed during the early stages of TJ formation (Cereijido et al., 1978). Quantitative microscopy and biochemical experiments suggest that this effect of IQGAP1 on TJ assembly is accounted for by reduced expression and TJ recruitment of claudin 2, and increased TJ recruitment of claudin 4. Furthermore, we show that IQGAP1 also regulates TJ formation through its interactor CDC42, because IQGAP1 knockdown increases the activity of the CDC42 effector JNK and dominant-negative CDC42 prevents the increase in TER caused by IQGAP1 silencing. Hence, we provide evidence that IQGAP1 modulates TJ formation by a twofold mechanism: (1) controlling the expression and recruitment of claudin 2 and recruitment of claudin 4 to the TJ, and (2) transient inhibition of the CDC42-JNK pathway.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, UK.
These authors contributed equally to this work
ISSN:0021-9533
1477-9137
DOI:10.1242/jcs.118703